Passage Bio (PASG)

• Market cap: $34.9M
• 1 day: -3.82%
• 5 days: -8.01%
• 1 month: -34.39%
• 3 months: 59.19%
• 6 months: 84.15%
• Year to date: -9.58%
• 1 year: -13.36%
• 5 years: -97.58%
• 10 years: -97.62%
• Sector: Healthcare
• Industry: Biotechnology

About: Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.

Employees: 60